HH
AVBP icon

HSG Holding’s ArriVent BioPharma AVBP Stock Holding History

HSG Holding’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14M Hold
663,308
– – 0.86% 9
2025
Q4 		$16.7M Hold
663,308
– – 0.88% 11
2025
Q3 		$13M Hold
663,308
– – 0.68% 9
2025
Q2 		$14.4M Hold
663,308
– – 0.74% 10
2025
Q1 		$14M Hold
663,308
– – 0.82% 7
2024
Q4 		$16.8M Hold
663,308
– – 0.69% 9
2024
Q3 		$19M Hold
663,308
– – 0.74% 9
2024
Q2 		$14.8M Hold
663,308
– – 0.55% 8
2024
Q1 		$10.5M Buy
+663,308
New +$13.4M 0.97% 10

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

HSG Holding's AVBP Position: Q1 2026 in Review

HSG Holding held its ArriVent BioPharma (AVBP) position steady in Q1 2026 at 663,308 shares worth $14M. The position accounts for 0.86% of the portfolio, ranked #9.

HSG Holding first reported a position in AVBP in Q1 2024 and has held it in 9 quarters since. The position peaked at $19M in Q3 2024. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • HSG Holding held 663,308 shares of ArriVent BioPharma worth $14M as of Q1 2026.
  • HSG Holding left its ArriVent BioPharma share count unchanged in Q1 2026.
  • ArriVent BioPharma made up 0.86% of HSG Holding's portfolio in Q1 2026, its #9 holding.
  • HSG Holding first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 9 quarters since.
  • HSG Holding's ArriVent BioPharma position peaked at $19M in Q3 2024.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on HSG Holding's 13F filing for Q1 2026, filed 15 May 2026.